Exelixis, Inc. (EXEL) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 70
- Profitability 75
- Business Quality 50
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 68/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Exelixis, Inc. (EXEL) is a Biotechnology company in the Healthcare sector. Compound Radar rates Exelixis, Inc. 68/100 (High Quality) due to solid business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 20.62
- Forward P/E 15.29
- PEG 2.56
- EV/Revenue 6.37
Profitability
- Revenue Growth 10.6%
- Operating Margin 39.5%
- Net Margin 35.3%
- ROE 44.4%
Financial strength
- Cash $839.39M
- Debt $165.93M
- Net Cash $673.46M
- Free Cash Flow $844.34M
- Current Ratio 3.46
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$17.25 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$116.60 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- ADMA Biologics, Inc. Biotechnology ADMA$11.06 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Innoviva, Inc. Biotechnology INVA$20.94 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$226.79 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$128.50 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$521.03 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Exelixis, Inc. (EXEL).